Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on EVGEN PHARMA PLC. We currently have 25 research reports from 4 professional analysts.
|05Dec16 07:00||RNS||Half Yearly Report|
|29Nov16 11:53||RNS||Hardman Research: Clinical sulforaphane potential|
|17Nov16 07:00||RNS||Notice of Interim Results|
|01Nov16 12:30||RNS||Grant of Options|
|15Sep16 07:00||RNS||Update re SFX-01 Data at ECTRIMS 2016|
|08Sep16 03:30||RNS||Presentation of SFX-01 Data at ECTRIMS 2016|
|24Aug16 03:15||RNS||Orphan Designation in the USA in SAH|
Frequency of research reports
Research reports on
EVGEN PHARMA PLC
EVGEN PHARMA PLC
Trial readouts expected in H1-2018
09 Dec 16
Evgen’s results were in line with our expectations. The group remains a good custodian of investor capital, managing a lean but productive operation. With £5.5m of cash on account (Sept. 30/2016), the Company has a strong balance sheet and is funded to complete its current clinical programmes. The group’s two Phase II clinical trials are progressing to plan, with both studies expected to report in H1-2018 (calendar year). Of note, over the period the group secured orphan designation for its lead product in the treatment of subarachnoid haemorrhage, representing a major milestone for the business. Also, the group recently presented very encouraging preclinical MS data.
06 Dec 16
"Markets quickly recovered their composure following the Prime Minister of Italy's shock resignation yesterday, with all major global indices closing in the positive. Near-term focus remains on the impact of international reflation, with investors asking whether the ECB's meeting on Thursday will be brave enough to conclude that the European economy is now sufficiently strong to propose cutting back the amount of bonds it stockpiles from the EUR80bn it has been buying every month since March. While such a possibility was signalled by Mario Draghi in an interview with Spanish newspaper El Pais last week, any tapering of its purchases would likely accelerate further the current sell-off in government bond markets, spiking yields and threatening stability of highly-indebted countries, like Italy, while also stunting growth in the region's more prosperous regions. Whatever, the expectation that Trump may oblige the Federal Reserve to effectively 'look the other way' as let the economy 'run hot' despite rising inflation continues to boost equities at the expense of Treasuries, as the Dow Jones hit yet another record high yesterday and technology stocks returned to favour sufficiently to push the NASDAQ up over 1%. Riding on the back of Wall Street, Asia was also firmer across the board, although the Shanghai Composite ended only just in the positive, as the traders considered Trump's latest criticisms of Chinese policy on social media to be a sign of tough trade and tariff negotiations to come. Almost adopting a 'if you can't beat them, join them' approach, the Bank of England's Mark Carney yesterday also entered the debate, calling on policy makers to pursue a better mix of fiscal, structural and monetary policies, noting that for too long central banks have been "the only game in town"; he also repeated earlier guidance provided by his officials that the Bank will be prepared to let annual inflation drift above its 2% target in order to support economic growth. Having seen this morning's BRC November same-store retail sales post 0.6% growth year-on-year, with the overall figure up 1.3%, no further significant macro data is expected from the UK today, although the US will release Factory Orders this afternoon. UK Corporates due to provide earnings or trading updates include Ashstead (AHT.L), Imagination Technologies (IMG.L), Northgate (NTG.L), On the Beach (OTB.L), Ultra Electronics (ULE.L), Vianet Group (VNET.L) and Wolseley (WOS.L). London is seen opening nervously this morning, with the FTSE-100 seen down 12 points in opening trade." - Barry Gibb, Research Analyst
Harnessing the clinical potential of sulforaphane
29 Nov 16
Evgen is a virtual pharmaceutical company focused on the development of a synthetic version of a natural product, sulforaphane, which is known to modulate key signalling pathways involved in cellular protection and inflammation. Evgen’s proprietary technology, Sulforadex, creates new and stable variants of sulforaphane, enabling it to be used as a therapeutic for the first time. Its lead candidate, SFX-01, has entered Phase II clinical trials for both subarachnoid haemorrhage (SAH) and ER+ metastatic breast cancer with an expected read out of results in 1H 2018.
08 Dec 16
Elderstreet stake acquired 02 GENERAL NEWS Globalworth premium In this issue Venture capital firm Draper Esprit has taken a 30.8% stake in venture capital trust manager Elderstreet. Both investment managers focus on the technology sector and they will be able to co-invest. Elderstreet has investments in a number of AIM-quoted companies through its VCTs. The purchase was funded by an issue of Draper Esprit shares worth just over £250,000. Simon Cook, the chief executive of Draper Esprit, is a former partner at Elderstreet so he knows the business and the people who run it, although he did leave more than 14 years ago. Cook has previously acquired portfolios from 3i and Cazenove, two other firms where he has worked. Draper Esprit has an option to acquire the remaining shares in Elderstreet, which has more than £25m under management. Adding Elderstreet to the group enables Draper Esprit to offer investors a range of EIS funds, VCTs and an ISA qualifying listed evergreen patient capital fund. The enlarged group has venture capital assets under management of more than £350m. At the end of September 2016, Draper Esprit had a net asset value of 352p a share, which is similar to the current share price. The June 2016 flotation price was 300p a share. Draper Esprit is quoted on Ireland’s Enterprise Securities Market as well as AIM.
N+1 Singer - Morning Song 05-12-2016
05 Dec 16
RTHM is acquiring a profitable Canadian listed mobile specialist for equivalent of US$42.5m consideration in shares (88.235m). This helps adds to two growth vectors RTHM is targeting; (i) adds unique exclusive audience (10m unique) and (ii) Exclusive demand Yahoo and Facebook. The business has 15 premium and owned and operated apps which provide users with rewards for activity. The business is expected to deliver c$9m of EBITDA in FY18 including $2m of cost synergies. This equates to just 4.7x EV/EBITDA. This marks what we see the first step in RTHM activity to scale the business and deliver on margin potential (see our initiation notes). Our initial estimates for EPS revisions are very significant - for FY18 are 2.3 cents (currently 0.6) and for FY19 4.3 (currently 2.5). There is a call at 830 for investors and we will revise post this.
Exponential growth now in sight
07 Dec 16
The best things in life are worth waiting for, or at least that seems to be the case with Kromek, a pioneering radiation detection expert. Since listing on AIM at 51p back in October 2013, the company has not only been busily refining and field testing its next generation CZT (cadmium zinc telluride) technology, but importantly also securing a raft of new orders.
N+1 Singer - Morning Song 09-12-2016
09 Dec 16
This morning’s AGM Statement confirms that trading in the first four months of the year to 31st October was in line with expectations. Revenue was slightly above the prior year period and cash collection has remained strong. The Group has reiterated its commitment to maintaining a progressive dividend policy. The statement is encouraging and we therefore leave our forecasts unchanged. We note the attractions of a 5% dividend yield and consider the shares inexpensive at 4.5x FY’17 EV/EBITDA.
Small Cap Breakfast
07 Dec 16
Creo Medical group—Schedule 1 update.. £20m raise. Expected market cap £61.2m, admission expected 9 December. ECSC—Schedule 1 from provider of cyber security services. Raising £5m. Vendor sale £0.8m. Target date 14 Dec. Expected market cap £15m. RM Secured Direct Lending - The secured direct lending fund intends to float on the Main Market on 15 December raising up to £100m
N+1 Singer - Morning Song 06-12-2016
06 Dec 16
With FY16 volume and revenue already disclosed in the pre-close, the focus in today’s prelims is on PBT (£100.3m versus our £101m) and EPS (96.8p versus our 95.4p). No special dividend triggered this year (none forecast) and DPS is held at 46.8p (N1SE: 48.0p). On end markets, recent commentary is reiterated – the core business is growing, whilst consumer electronics will be subdued in the current year (competitive capacity from Solvay). On currency, there will be a material benefit in the current year (a little more than the £14m to £15m previously indicated), and a further tailwind next year if current rates are maintained (quantum TBC). There is also an investment of £10m today in a minority interest in Magma Global, Victrex’ oil and gas mega programme partner. Although the share price is now close to our TP of 1730p, we feel that there is enough in today’s announcement to retain a positive stance on medium term opportunities with strong cashflow and a special dividend potentially to look forward to in the current year.